JOP20210324A1 - مشتقات من 2h-indazole واستخدامها في علاج مرض - Google Patents
مشتقات من 2h-indazole واستخدامها في علاج مرضInfo
- Publication number
- JOP20210324A1 JOP20210324A1 JOP/2021/0324A JOP20210324A JOP20210324A1 JO P20210324 A1 JOP20210324 A1 JO P20210324A1 JO P20210324 A JOP20210324 A JO P20210324A JO P20210324 A1 JOP20210324 A1 JO P20210324A1
- Authority
- JO
- Jordan
- Prior art keywords
- disease
- treatment
- indazole derivatives
- further provides
- invention further
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
غير متوفر
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867521P | 2019-06-27 | 2019-06-27 | |
PCT/US2020/039346 WO2020263967A1 (en) | 2019-06-27 | 2020-06-24 | 2h-indazole derivatives and their use in the treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210324A1 true JOP20210324A1 (ar) | 2023-01-30 |
Family
ID=71608086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0324A JOP20210324A1 (ar) | 2019-06-27 | 2020-06-24 | مشتقات من 2h-indazole واستخدامها في علاج مرض |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230002361A1 (ar) |
EP (1) | EP3990432A1 (ar) |
JP (1) | JP2022539374A (ar) |
KR (1) | KR20220042132A (ar) |
CN (1) | CN114585609A (ar) |
AR (1) | AR119244A1 (ar) |
AU (1) | AU2020304036A1 (ar) |
BR (1) | BR112021026369A2 (ar) |
CA (1) | CA3145043A1 (ar) |
CL (1) | CL2021003458A1 (ar) |
CO (1) | CO2022000657A2 (ar) |
CR (1) | CR20220036A (ar) |
IL (1) | IL289167A (ar) |
JO (1) | JOP20210324A1 (ar) |
MA (1) | MA56392A (ar) |
MX (1) | MX2021015499A (ar) |
PE (1) | PE20220517A1 (ar) |
TW (1) | TW202116735A (ar) |
UY (1) | UY38765A (ar) |
WO (1) | WO2020263967A1 (ar) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
WO2022140425A1 (en) * | 2020-12-22 | 2022-06-30 | Biogen Ma Inc. | Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease |
CN116940572A (zh) * | 2020-12-22 | 2023-10-24 | 渤健马萨诸塞州股份有限公司 | 作为irak4抑制剂的2h-吲唑衍生物及其在治疗疾病中的用途 |
EP4367113A1 (en) * | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
CN113651810B (zh) * | 2021-07-16 | 2023-10-13 | 上海毕得医药科技股份有限公司 | 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法 |
WO2023152349A1 (en) | 2022-02-14 | 2023-08-17 | Astrazeneca Ab | Irak4 inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
AR050253A1 (es) * | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
EP2007733B1 (en) * | 2006-04-03 | 2016-05-25 | MSD Italia S.r.l. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
WO2008030584A2 (en) * | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase |
US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
BG111378A (bg) * | 2013-01-14 | 2015-01-30 | Николай Цветков | Субституирани индазолови производни като in-vitro mao-b инхибитори |
JP6503338B2 (ja) * | 2013-03-15 | 2019-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | Hdac阻害剤 |
CA2958508A1 (en) * | 2014-08-22 | 2016-02-25 | Merck Patent Gmbh | Indazoles |
JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
BR112018000624A2 (pt) * | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | compostos de indazol e azaindazol como inibidores de irak-4 |
CN105503863A (zh) * | 2015-12-11 | 2016-04-20 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
CN105559944B (zh) * | 2015-12-14 | 2016-11-09 | 李雷 | 覆膜血管支架 |
CN109153665B (zh) * | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
-
2020
- 2020-06-24 KR KR1020227003147A patent/KR20220042132A/ko unknown
- 2020-06-24 JO JOP/2021/0324A patent/JOP20210324A1/ar unknown
- 2020-06-24 UY UY0001038765A patent/UY38765A/es unknown
- 2020-06-24 PE PE2021002236A patent/PE20220517A1/es unknown
- 2020-06-24 TW TW109121728A patent/TW202116735A/zh unknown
- 2020-06-24 AU AU2020304036A patent/AU2020304036A1/en not_active Abandoned
- 2020-06-24 WO PCT/US2020/039346 patent/WO2020263967A1/en active Application Filing
- 2020-06-24 CR CR20220036A patent/CR20220036A/es unknown
- 2020-06-24 CA CA3145043A patent/CA3145043A1/en active Pending
- 2020-06-24 JP JP2021577477A patent/JP2022539374A/ja active Pending
- 2020-06-24 MX MX2021015499A patent/MX2021015499A/es unknown
- 2020-06-24 CN CN202080053737.3A patent/CN114585609A/zh active Pending
- 2020-06-24 MA MA056392A patent/MA56392A/fr unknown
- 2020-06-24 US US17/623,182 patent/US20230002361A1/en active Pending
- 2020-06-24 BR BR112021026369A patent/BR112021026369A2/pt not_active Application Discontinuation
- 2020-06-24 EP EP20740146.4A patent/EP3990432A1/en active Pending
- 2020-06-24 AR ARP200101792A patent/AR119244A1/es unknown
-
2021
- 2021-12-20 IL IL289167A patent/IL289167A/en unknown
- 2021-12-23 CL CL2021003458A patent/CL2021003458A1/es unknown
-
2022
- 2022-01-25 CO CONC2022/0000657A patent/CO2022000657A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022000657A2 (es) | 2022-04-29 |
CN114585609A (zh) | 2022-06-03 |
KR20220042132A (ko) | 2022-04-04 |
TW202116735A (zh) | 2021-05-01 |
BR112021026369A2 (pt) | 2022-05-17 |
CR20220036A (es) | 2022-05-04 |
UY38765A (es) | 2021-01-29 |
IL289167A (en) | 2022-02-01 |
AR119244A1 (es) | 2021-12-01 |
MA56392A (fr) | 2022-05-04 |
CL2021003458A1 (es) | 2022-08-19 |
WO2020263967A1 (en) | 2020-12-30 |
MX2021015499A (es) | 2022-04-20 |
CA3145043A1 (en) | 2020-12-30 |
JP2022539374A (ja) | 2022-09-08 |
EP3990432A1 (en) | 2022-05-04 |
AU2020304036A1 (en) | 2022-01-06 |
PE20220517A1 (es) | 2022-04-07 |
US20230002361A1 (en) | 2023-01-05 |
WO2020263967A8 (en) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210324A1 (ar) | مشتقات من 2h-indazole واستخدامها في علاج مرض | |
JOP20210322A1 (ar) | مشتقات من إيميدازو[1 ،2-a] بيريدينيل واستخدامها في علاج مرض | |
MX2021007592A (es) | Compuestos macrociclicos y su uso en el tratamiento de enfermedades. | |
PH12018500162A1 (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
MX2019002439A (es) | Derivados de n-(piridin-2-il) piridina-sulfonamida y su uso en el tratamiento de enfermedades. | |
MX2021000737A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y composicion farmaceutica que los comprende. | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
MX2020010034A (es) | Metodo de tratamiento de enfermedad fibrotica. | |
CO2023009316A2 (es) | Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades | |
MX2021012579A (es) | Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos. | |
CR20230318A (es) | Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades | |
WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
WO2019014322A8 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES | |
MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
AU2019284008A1 (en) | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders | |
EP4324522A3 (en) | Methods of treating fabry patients having renal impairment | |
Steinbach et al. | High-Frequency Spinal Cord Stimulation at 10 kHz for the Treatment of Chronic Neuropathic Pain After a II–III Degree Burn | |
MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
Wu | Toxic epidermal necrolysis: case report | |
AU2023903475A0 (en) | Treatment methods for inherited retinal diseases | |
AU2022903363A0 (en) | Treatment methods for inherited retinal diseases | |
UA128597U (uk) | Спосіб лікування цереброваскулярних порушень головного мозку |